The catalytic domain of free or ligand bound histone deacetylase 4 occurs in solution predominantly in closed conformation
AbstractHuman histone deacetylase 4 (HDAC4) is a key epigenetic regulator involved in a number of important cellular processes. This makes HDAC4 a promising target for the treatment of several cancers and neurodegenerative diseases, in particular Huntington's disease. HDAC4 is highly regulated by phosphorylation and oxidation, which determine its nuclear or cytosolic localization, and exerts its function through multiple interactions with other proteins, forming multiprotein complexes of varying composition. The catalytic domain of HDAC4 is known to interact with the SMRT/NCOR corepressor complex when the structural zinc-b...
Source: Protein Science - February 15, 2024 Category: Biochemistry Authors: Markus Schweipert,
Thomas Nehls,
Anton Fr ühauf,
Cecilé Debarnot,
Adarsh Kumar,
Stefan Knapp,
Frederik Lermyte,
Franz‐Josef Meyer‐Almes Tags: RESEARCH ARTICLE Source Type: research
Pooling of primary care electronic health record (EHR) data on Huntingtons disease (HD) and cancer: establishing comparability of two large UK databases
Conclusions
Differences in cancer incidence trends between 1990 and 2000 may relate to use of a practice-level data quality filter (the ‘up-to-standard’ date) in CPRD GOLD only. As well as the impact of data curation methods, differences in underlying data models can make it more challenging to define exactly equivalent clinical concepts in each database. Researchers should be aware of these potential sources of variability when planning combined database studies and interpreting results. (Source: BMJ Open)
Source: BMJ Open - February 14, 2024 Category: General Medicine Authors: Dedman, D., Williams, R., Bhaskaran, K., Douglas, I. J. Tags: Open access, Epidemiology Source Type: research
Huntington disease – Update on ongoing therapeutic developments and a look toward the future
Huntington's disease (HD) is a genetic condition inherited in an autosomal dominant pattern characterized by neurodegeneration. The root cause of HD is a CAG tract expansion occurring in exon 1 of the huntingtin (HTT) gene. This mutation sets in motion a series of detrimental events that progressively lead to neuronal death and structural changes, mainly within the central nervous system but also affecting other organs [1]. Currently, no disease-modifying treatments for HD exist, but an active research effort focuses on potential therapies, with programs in various stages of development. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - February 13, 2024 Category: Neurology Authors: Cristina Sampaio Tags: Review article Source Type: research
